D
David Y. Mason
Researcher at John Radcliffe Hospital
Publications - 186
Citations - 16584
David Y. Mason is an academic researcher from John Radcliffe Hospital. The author has contributed to research in topics: Antigen & Lymphoma. The author has an hindex of 69, co-authored 186 publications receiving 16112 citations. Previous affiliations of David Y. Mason include University of Oxford & State University of New York System.
Papers
More filters
Journal ArticleDOI
Transferrin receptor on endothelium of brain capillaries
Wilfred A. Jefferies,Malcolm R. Brandon,Simon V. Hunt,Alan F. Williams,Kevin C. Gatter,David Y. Mason +5 more
TL;DR: It is shown that monoclonal antibodies against rat and human transferrin receptors label blood capillaries in the brain but not in other tissues, suggesting that transferrin receptor expression on neuronal and glial cells may allow transport of transferrin into brain tissues.
Journal ArticleDOI
bcl-2 Protein in Non-Small-Cell Lung Carcinoma
Francesco Pezzella,Helen Turley,Isinzu Kuzu,Mohammed Fahim Tungekar,Michael S. Dunnill,Chris B. Pierce,Adrian L. Harris,Kevin C. Gatter,David Y. Mason +8 more
TL;DR: The proto-oncogene bcl-2 is abnormally expressed in some lung carcinomas, and its expression may have prognostic importance.
Journal ArticleDOI
Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases
Stefano Pileri,T. M. Grogan,Nancy L. Harris,Peter A. Banks,Elias Campo,John K.C. Chan,Riccardo Dalla Favera,Georges Delsol,C De Wolf-Peeters,Brunangelo Falini,Randy D. Gascoyne,P. Gaulard,Kevin C. Gatter,Peter G. Isaacson,Elaine S. Jaffe,Philippus Kluin,Daniel M. Knowles,David Y. Mason,Shigeo Mori,H.K. Müller-Hermelink,M A Piris,E. Ralfkiaer,H Stein,Ih-Jen Su,Roger A. Warnke,Lawrence M. Weiss +25 more
TL;DR: Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases shows clear trends in prognosis and disease progression.
Journal ArticleDOI
ALK-Positive Lymphoma: A Single Disease With a Broad Spectrum of Morphology
Daniel Benharroch,Zarouhie Meguerian-Bedoyan,Laurence Lamant,Chauki Amin,Laurence Brugières,Marie Jose Terrier-Lacombe,Eugenia Haralambieva,Karen Pulford,Stefano Pileri,Stephan W. Morris,David Y. Mason,Georges Delsol +11 more
TL;DR: It is concluded from this study that ALK-positive neoplasms represent a distinct entity and should henceforward be referred to as ALK lymphomas.
Journal ArticleDOI
A human thymocyte antigen defined by a hybrid myeloma monoclonal antibody.
TL;DR: Spleen cells from a BALB/c mouse that had been immunized with human thymocytes were fused with the myeloma line P3‐NS1/1Ag 4.1 and one of the resulting hybrid clones secreted an antibody that was highly specific for humanThymocytes, designated HTA1.